EPS for Ocular Therapeutix, Inc. (OCUL) Expected At $-0.34

October 13, 2018 - By Michael Collier

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Logo

Analysts expect Ocular Therapeutix, Inc. (NASDAQ:OCUL) to report $-0.34 EPS on November, 6.They anticipate $0.20 EPS change or 37.04 % from last quarter’s $-0.54 EPS. After having $-0.37 EPS previously, Ocular Therapeutix, Inc.’s analysts see -8.11 % EPS growth. It closed at $6.08 lastly. It is down 1.38% since October 14, 2017 and is uptrending. It has underperformed by 14.24% the S&P500.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Coverage

Among 2 analysts covering Ocular Therapeutix (NASDAQ:OCUL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ocular Therapeutix had 3 analyst reports since May 8, 2018 according to SRatingsIntel. The stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) has “Buy” rating given on Tuesday, May 8 by Cantor Fitzgerald. H.C. Wainwright maintained Ocular Therapeutix, Inc. (NASDAQ:OCUL) rating on Thursday, June 21. H.C. Wainwright has “Buy” rating and $1000 target. H.C. Wainwright maintained Ocular Therapeutix, Inc. (NASDAQ:OCUL) rating on Wednesday, May 9. H.C. Wainwright has “Buy” rating and $1000 target.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology. The company has market cap of $234.64 million. The Company’s product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms. It currently has negative earnings. The company's lead product candidate, DEXTENZA 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Another recent and important Ocular Therapeutix, Inc. (NASDAQ:OCUL) news was published by Seekingalpha.com which published an article titled: “Ocular Therapeutix amends license deal with Incept” on September 19, 2018.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.